Abstract
It has become increasingly evident that our current therapeutic options in the treatment of sepsis are limited and result in an unacceptable high mortality rate. The outcome in severe sepsis and septic shock has not changed appreciably despite improvements in critical care medicine and the introduction of a number of potent, broad-spectrum antimicrobial agents over the past two decades. Septic shock has become a leading cause of mortality in critical care units and current trends would indicate that sepsis will become increasingly common in the future. Clearly, innovative treatment strategies are needed to support the septic patient and improve the outlook in this potentially devastating clinical Syndrome [1].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bone RC (1991) Pathogenesis of Sepsis. Ann Intern Med 115: 457–469
Dinarello CA (1991) The proinflammatory cytokines interleukin-1 and tumor necrosis factor in the treatment of septic shock Syndrome. J Inf Dis 136: 1177–1184
Seckinger P, Lowenthal JW, Williamson K, Dayer J, McDonald HR (1987) A urine inhibitor of interleukin-1 activity that blocks ligand binding. J Immunol 139: 1546–1549
Dinarello CA (1988) Biology of interleukin-1. FASEB J 2: 108–115
Oppenheim JJ, Matsushima K, Yoshimura T, Leonard EJ, Nata R (1989) Relationship between interleukin-1 (IL-1), tumor necrosis factor (TNF) and a neutrophil attracting peptide (NAP-1). Agents Actions 26: 134–140
Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA (1988) Interleukin-1 induces a shock-like State in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxyge- nase inhibition. J Clin Invest 81: 1162–1172
Arend WP, Joslin FG, Thompson RC, Hannum CH (1989) An IL-1 inhibitor from human mo- nocytes. Production and characterization of biologic properties. J Immunol 143: 1851–1858
Seckinger P, Dayer JM (1987) Interleukin-1 inhibitors. Ann Inst Pasteur/Immunol 138: 461–516
Eisenberg SP, Evans RJ, Arend WP, et al. (1990) Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343: 141–146
Dinarello CA, Thompson RC (1991) Bloeking IL-1: Interleukin-1 receptor antagonist in vivo and in vitro. Immunol Today 12: 404–410
Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces modality from endotoxin shock. Nature 348: 550–552
Fischer E, Marino MA, VanZee KJ, et al. (1992) Interleukin-1 receptor blockade improves survival and hemodynamic Performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 89: 1551–1557
Aiura K, Gelfand JA, Wakabayashi G, et al. (1991) Interleukin-1 receptor antagonist blocks hypotension in a rabbit mpdel of gram-positive septic shock. Cytokine 3: 498
Granowitz EV, Porat R, Mier JW, et al. (1992) Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 4: 353–360
Granowitz EV, Santos AA, Poutsiaka DD, et al. (1991) Production of interleukin-1 receptor antagonist during experimental endotoxaemia. Lancet 33A: 1423–1424
Fisher CJ, Slotman G, Opal S, Pribble J, Catalano M, and the IL-lra Sepsis Study Group (1991) Results of a phase II study of IL-lra in the treatment of sepsis Syndrome. American College of Chest Physicians 57th Annual Meeting San Francisco California
Opal SM, Fischer CJ, Slotman GJ, et al., and the IL-lra Sepsis Study Group (1992) Phase II interleukin-1 receptor antagonist sepsis Syndrome trial: Analysis of clinical, cytokine, and microbial features with outcome. 32nd Annual Meeting of the Interscience Conference of Antimicrobial Agents and Chemotherapy, Anaheim California Abst 1570
Gordon G, Fisher CJ, Opal SM, Pribble J, Catalano M (1992) Cost-effectiveness of interleukin-1 receptor antagonist in sepsis. Clin Res 40 (Abst) 254 A
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Opal, S.M. (1993). IL-1ra as a Therapeutic Modality in Sepsis. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine 1993. Yearbook of Intensive Care and Emergency Medicine 1993, vol 1993. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84904-6_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-84904-6_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-56463-8
Online ISBN: 978-3-642-84904-6
eBook Packages: Springer Book Archive